Why Heron Therapeutics Stock Is Crashing Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average daily volume. This double-digit move lower was sparked by a $150 million public offering of its common stock.
Heron reportedly plans on using the proceeds from this secondary offering to support the ongoing commercial launches of its medicines for chemotherapy-induced nausea, Sustol and Cinvanti, as well as to fund its clinical activities.
Image source: Getty Images.
Source: Fool.com
Heron Therapeutics Inc. Aktie
0,27 €
6,69 %
Mehr Buy- als Sell-Zahlen bei Heron Therapeutics Inc. zeigen ein leicht positives Sentiment.
Das Kursziel von 3 € für Heron Therapeutics Inc. impliziert eine potenzielle Verdopplung gegenüber dem aktuellen Kurs von 0.27 €.
